Mike Tyson says psychedelics saved his life, now he hopes they can change the wo

[[Fi...]]

https://www.reuters.com/lifestyle/sports/mike-tyson-says-psychedelics-saved-his-life-now-he-hopes-they-can-change-world-2021-05-28/?fbclid=IwAR3dRGm1Lt4xTbz1R_E6uCt3OUjl4yJIbKztPM-36IB_-weFBlZUw_LnSH0

 

Mike Tyson says psychedelics saved his life, now he hopes they can change the world

 

"During his reign as heavyweight champion of the world, no one was more feared than Mike Tyson, who obliterated opponents with ruthless efficiency.

 

But all the while, the troubled superstar was at war with himself, battling an abusive voice in his battered head that led "Iron Mike" to the brink of suicide.

 

He said that all changed when he began taking psilocybin mushrooms, more commonly known as "magic mushrooms," and other similar consciousness-altering substances.

 

Now the boxing prodigy from Brooklyn is experiencing a career renaissance that he said is the result of psilocybin-powered mental and spiritual exploration.

 

"Everyone thought I was crazy, I bit this guy's ear off," an upbeat Tyson told Reuters, referring to his infamous 1997 fight against Evander Holyfield.

 

"I did all this stuff, and once I got introduced to the shrooms ... my whole life changed."

 

To be sure, many people have had negative experiences with psilocybin, which can cause disturbing hallucinations, anxiety and panic. Medical professionals studying them warn against self-medicating or using them outside of an approved medical framework.

 

But Tyson, who turns 55 next month, and impressed in his November exhibition bout against Roy Jones Jr, said he has never felt better.

"It's scary to even say that," said Tyson, who is also a cannabis entrepreneur and podcast host.

 

"To think where I was - almost suicidal - to this now. Isn't life a trip, man? It's amazing medicine, and people don't look at it from that perspective."

 

"I AM CURED"

 

Humans have been ingesting psychedelics since the earliest days and as stigmas slowly dissolve, it is beginning to be taken seriously as a psychiatric medicine.

 

There is still much to learn.

 

Enter former NHL enforcer Daniel Carcillo, who was nicknamed "Car Bomb" for his violent approach to the sport.

After 164 fights, thousands of hits and at least seven concussions, the two-time Stanley Cup champion was forced to retire in 2015 due to repeated head trauma.

 

Like Tyson, he was at war with himself and struggling to connect with his wife and young children after his retirement at age 30.

 

He said psilocybin helped him bridge that gap and the experience led him to found Wesana Health, a first-of-its-kind company dedicated to studying its ability to treat traumatic brain injury (TBI) in athletes, veterans and others.

 

Wesana recently entered into a clinical research project with the World Boxing Council (WBC) to examine the potential of psilocybin to help boost the brain health of boxers, and Carcillo says he is proof that it works.

 

"I am cured, for sure, of TBI and any related symptoms. 100%," Carcillo said.

 

"I do not suffer from slurred speech, headaches, head pressure, insomnia, impulse control issues, anxiety, depression or suicidal ideation," he said.

 

"I do not suffer from any of that (anymore)."

 

Carcillo and his team are hopeful psilocybin will become an FDA-approved drug to treat TBI.

 

OPEN TO THE WORLD

 

Tyson said he wants to spread word of the benefits of psilocybin as widely as possible, which is why he has partnered with Wesana.

 

"I believe this is good for the world," said Tyson, who said he thinks its use could also help create a more empathetic and just society.

 

"If you put 10 people in a room that don't like each other and give them some psychedelics, they'll be taking pictures with each other," he said.

 

"Put 10 people in a room who don't like each other and give them some liquor, and they'll be shooting everybody. That's real talk.

 

"(Wesana) was on the same level of thinking that I was. They wanted to share this with the world. This is very limited, us doing this in these small ceremonies.

 

"It needs to be open to the world."

 

 

[[Fi...]]

Quote from message from Piano Girl:

 

"From: pianogirl

I've moved your post about psilocybin to the Off Topic board since it has nothing to do with benzos.

 

http://www.benzobuddies.org/forum/index.php?topic=256569.0

 

pianogirl"

 

 

[[Fi...]]

Quote from message from Piano Girl:

 

"From: pianogirl

I've moved your post about psilocybin to the Off Topic board since it has nothing to do with benzos.

 

http://www.benzobuddies.org/forum/index.php?topic=256569.0

 

pianogirl"

 

From: fi addendum

To: Piano Girl

 

Re: Moving of post from "Benzos in The News" to "Off Topic"

 

This article and a host of other research publications do indeed have to do with benzodiazepines in that benzodiazepines are associated with traumatic brain injuries.

 

If you wish for me to provide some quality research publications which associate traumatic brain injury, benzodiazepines, and naturally occurring and synthetically produced compounds like psilocybin which are currently being used and researched to treat the symptoms of traumatic brain injuries, I can do that.

[[Bo...]]

Why was this put off topic? Philosophy is a topic. Psychedelics change your perspective and give philosophy which perhaps snap you out of such anxiety if that is your issue.

[[Fi...]]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082376/

 

"Psychedelics Promote Structural and Functional Neural Plasticity"

 

SUMMARY

 

Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo. These changes in neuronal structure are accompanied by increased synapse number and function, as measured by fluorescence microscopy and electrophysiology. The structural changes induced by psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling pathways and could possibly explain the clinical effectiveness of these compounds. Our results underscore the therapeutic potential of psychedelics and, importantly, identify several lead scaffolds for medicinal chemistry efforts focused on developing plasticity-promoting compounds as safe, effective, and fast-acting treatments for depression and related disorders.

 

 

[[Fi...]]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082376/

 

"Psychedelics Promote Structural and Functional Neural Plasticity"

 

SUMMARY

 

Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo. These changes in neuronal structure are accompanied by increased synapse number and function, as measured by fluorescence microscopy and electrophysiology. The structural changes induced by psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling pathways and could possibly explain the clinical effectiveness of these compounds. Our results underscore the therapeutic potential of psychedelics and, importantly, identify several lead scaffolds for medicinal chemistry efforts focused on developing plasticity-promoting compounds as safe, effective, and fast-acting treatments for depression and related disorders.

 

Mentioned in the above article is the patent application (PCT/US2017/054277) from David E. Olson. Here is a link to that patent application entitled "Compounds for increasing neural plasticity" https://patents.google.com/patent/WO2018064465

 

Abstract

 

The present invention provides a method of using non-hallucinogenic analogs of psychedelic compounds for increasing neural plasticity of the neuronal cell, and a method of using thereof for treating a brain disorder.

.

.

Claims

 

WHAT IS CLAIMED IS: 1. A method for increasing neural plasticity, comprising contacting a neuronal cell with a non-hallucinogenic analog of a psychedelic compound, in an amount sufficient to increase neural plasticity of the neuronal cell, wherein the non-hallucinogenic analog of a psychedelic compound produces a maximum number of dendritic crossings with an increase of greater than 1.0 fold by a Sholl Analysis.

2. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound produces an area-under-curve (AUC) of a Sholl plot with an increase of greater than 1.0 fold.

3. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound produces a number of dendritic branches with an increase of greater than 1.0 fold.

4. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound produces a total dendritic length with an increase of greater than 1.0 fold.

5. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound produces a density of dendritic spines with an increase of greater than 1.0 fold.

6. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound produces a density of synapses with an increase of greater than 1.0 fold.

7. The method of claim 6, wherein the non-hallucinogenic analog of a psychedelic compound produces a density of a presynaptic protein with an increase of greater than 1.0 fold, wherein the presynaptic protein is Vesicular glutamate transporter 1 (VGLUT1).

8. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound increases at least one of translation, transcription, and secretion of neurotrophic factors.

9. The method of claim 8, wherein the neurotrophic factor is at least one of a brain-derived neurotrophic factor (BDNF) and a glial cell line-derived neurotrophic factor (GDNF).

10. The method of claim 9, wherein the translation of the brain-derived neurotrophic factor (BDNF) has an increase of greater than 1.0 fold.

11. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a blood-brain-barrier (BBB) penetrator.

12. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound has a pKa of from 7.0 to 10.0.

13. The method of claim 12, wherein the non-hallucinogenic analog of a psychedelic compound is permeable across cell membranes.

14. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula la or lb:

Figure imgf000069_0001

wherein:

L1 is a bond, -C(0)NRa-, -NRaC(0)-, -NHC(0)NRa-, -C(0)NRaC(0)NH-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRa-, -NHS02-, -SO2-. -0-, -S-, or -NRa-;

R1 is hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6 haloalkyl, Ci C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, aryl, heterocycloalkyl, or heteroaryl; L2 is a bond, -C(0) Ra-, - RaC(0)-, - HC(0)NRa-, -C(0)0-, -OC(O)-, - HC(0)0-, -S02 Ra-, - HS02-, -S02-. -0-, -S-, or - Ra-;

R2 is independently hydrogen, halogen, -OH, Ci-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, aryl, heterocycloalkyl, or heteroaryl;

Ra is hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, or Ci-C6 aminoalkyl;

R3 is hydrogen, Ci-C6 alkyl, or C2-C6 alkenyl;

R4 is hydrogen, halogen, Ci-C6 alkyl, C2-C6 alkenyl, or Ci-C6 haloalkyl;

R5 is Ci-Ce alkyl or C2-C6 alkenyl;

R6 is hydrogen, halogen, -OH, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce hydroxyalkyl, or Ci-C6 alkoxy; and

R7 is hydrogen, -OH, Ci-C6 alkyl, Ci-C6 hydroxyalkyl, or Ci-C6 alkoxy; and subscripts m and n are independently an integer from 0 to 3.

15. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is selected from the group consisting of Ergometrine,

Dihydroergotamine, Methylergometrine, Methysergide, Ergotamine, Cabergoline, Pergolide, Lisuride, 2-Bromo-lysergic acid diethylamide (BOL-148), Nicergoline, and Bromocriptine.

16. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is a compound of Formula Ila or lib:

Figure imgf000070_0001

wherein:

L3 is a bond, -C(0)NRb-, -NRbC(0)-,-NHC(0)NRb-, -C(0)0-, -OC(O)-, -NHC(0)0-, -S02NRb-, -NHS02-, -S02-, -0-, -S-, or -NRb-; R is hydrogen, halogen, Ci-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 hydroxyalkyl, Ci-C6 alkoxy, Ci-C6 aminoalkyl, heterocycloalkyl, aryl, or heteroaryl;

Rb is hydrogen, Ci-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, Ci-C6 haloalkyl, Ci-C6 hydroxyalkyl, or Ci-C6 alkoxy;

R9 is hydrogen, Ci-C6 alkyl, or C2-C6 alkenyl;

R10 is hydrogen, halogen, Ci-C6 alkyl, C2-C6 alkenyl, or Ci-C6 haloalkyl;

R11 is Ci-C6 alkylamino, di-(Ci-C6 alkyl)amino, N-(Ci-C6 alkyl)pyrrolidinyl, or N-(Ci-C6 alkyl)piperidinyl;

R12 is hydrogen, halogen, -OH, Ci-C6 alkyl, Ci-C6 haloalkyl, Ci-C6 hydroxyalkyl, or Ci-C6 alkoxy;

R13 is Ci-C6 alkylamino or di-(Ci-C6 alkyl)amino;

subscript p is an integer from 0 to 3;

subscript q is an integer from 0 to 3; and

subscript r is an integer from 1 to 3.

17. The method of claim 1, wherein the non-hallucinogenic analog of a psychedelic compound is selected from the group consisting of Sumatriptan, Zolmitriptan, Rizatriptan, Eletriptan, Naratriptan, Frovatriptan, Almotriptan, 6-methoxy-N,N- dimethyltryptamine, and 6-fluoro-N,N-dimethyltryptamine.

18. A method of treating a brain disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a non-hallucinogenic analog of a psychedelic compound, thereby treating the brain disorder, wherein the non-hallucinogenic analog of a psychedelic compound increases neural plasticity of the neuronal cell;

provided that the subject is not already being treated with one or more of following:

Ergometrine for postpartum hemorrhage and postabortion hemorrhage due to uterine atony; the subject is not treated with Dihydroergotamine for migraines or cluster headaches;

Methylergometrine for routine management after delivery of the placenta, postpartum atony and hemorrhage, subinvolution, or migraines;

Methysergide for migraines or cluster headaches; Ergotamine for migraines or cluster headaches;

Cabergoline for hyperprolactinemic disorders or Parkinson's disease; Pergolide for Parkinson's disease;

Lisuride for Parkinson's disease;

Nicergoline for senile dementia or other disorders with vascular origins;

Bromocriptine for pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, or type 2 diabetes; or

Sumatriptan, Zolmitriptan, Rizatriptan, Eletriptan, Naratriptan, Frovatriptan, or Almotriptan for migraines or cluster headaches.

19. The method of claim 18, wherein the brain disorder is a psychiatric disorder selected from the group consisting of depression, anxiety, and post-traumatic stress disorder.

20. The method of claim 18, wherein the brain disorder is a substance use disorder.

21. The method of claim 18, wherein the brain disorder is a neurodegenerative disorder selected from the group consisting of Alzhemier's and Parkinson's diseases. (Some formatting errors occurred from this copy & paste)

 

Personally, I am most familiar with the "non-hallucinogenic analog of a psychedelic compound" called Sumatriptan (Imitrex) for the treatment of cluster headache symptoms. It is the only pharmaceutical treatment that I've found to sufficiently treat the debilitating symptoms associated with this medical condition. I'm familiar with many people with this condition who have had as good or better success with the naturally occurring mushroom called Psilocybe cubensis which can also easily be grown at one's home.

[[Fi...]]

"Guy Challenges Mike Tyson to Fight, Pulls Gun at Comedy Show"